Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.
The Oncologist|April 26, 2019
Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated LiposarcomaKate Lynn J Bill, Nathan D Seligson, John L Hays, et al.
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences|January 15, 2026
Advancing equity in collaborative research: reflections from the Cultural Evolution Society Transformation FundAdam H Boyette, Jessica E M van der Wal, David W Lawson, et al.
Annals of Surgical Oncology|June 25, 2025
Consensus Guideline for the Management of Peritoneal MesotheliomaLeanne M Brown, Sarah G Wilkins, Varun V Bansal, et al.
Cancer|June 25, 2025
Consensus guideline for the management of peritoneal mesotheliomaLeanne M Brown, Sarah G Wilkins, Varun V Bansal, et al.
Cancer Chemotherapy and Pharmacology|October 23, 2020
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumorsKhanh T Do, Geraldine O'Sullivan Coyne, John L Hays, et al.
Emerging Infectious Diseases|February 7, 2008
Spectrum of infection and risk factors for human monkeypox, United States, 2003Mary G Reynolds, Whitni B Davidson, Aaron T Curns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction AdenocarcinomaManish A Shah, Kohei Shitara, Florian Lordick, et al.
Future Oncology (London, England)|June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancerThomas J Herzog, John L Hays, Joyce N Barlin, et al.
Pageof 17